KYMR: Accelerated STAT6 program advances toward Phase III, targeting first-in-class oral therapies

Revised summary: The conference highlighted rapid STAT6 program progress, with accelerated enrollment and strong early data supporting Phase III for atopic dermatitis and asthma. Focus areas include pediatric expansion, multiple indications, and IRF5 pipeline innovation. Long-term safety and effica…